The multicenter randomized controlled trial aims to evaluate the efficacy of HD-tDCS in patients with Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease with significant unmet medical needs. The trial's focus on respiratory function and disease progression positions it strategically within the ALS treatment landscape, which currently lacks effective therapies. If successful, this intervention could provide a novel non-invasive treatment option, potentially capturing market share in a niche but critical segment of neuromodulation therapies. The trial is sponsored by Universidade Federal do Rio Grande do Norte, indicating a strong academic backing, which may enhance credibility and attract future partnerships or funding opportunities. Competitive implications include the need to monitor other neuromodulation approaches and therapies targeting ALS, as well as the broader market for neurostimulation devices.